Angiogenesis

pp 1–10

A novel strategy to enhance angiogenesis in vivo using the small VEGF-binding peptide PR1P

  • Avner Adini
  • Irit Adini
  • Zai-long Chi
  • Ratmir Derda
  • Amy E. Birsner
  • Benjamin D. Matthews
  • Robert J. D’Amato
Brief Communication

DOI: 10.1007/s10456-017-9556-7

Cite this article as:
Adini, A., Adini, I., Chi, Z. et al. Angiogenesis (2017). doi:10.1007/s10456-017-9556-7

Abstract

Therapeutic angiogenesis is an experimental frontier in vascular biology that seeks to deliver angiogenic growth factors to ischemic or injured tissues to promote targeted formation of new blood vessels as an alternative approach to surgical revascularization procedures. Vascular endothelial growth factor (VEGF) is a potent angiogenic signal protein that is locally upregulated at sites of tissue injury. However, therapies aimed at increasing VEGF levels experimentally by injecting VEGF gene or protein failed to improve outcomes in human trials in part due to its short half-life and systemic toxicity. We recently designed a novel 12-amino acid peptide (PR1P) whose sequence was derived from an extracellular VEGF-binding domain of the pro-angiogenic glycoprotein prominin-1. In this study, we characterized the molecular binding properties of this novel potential therapeutic for targeted angiogenesis and provided the foundation for its use as an angiogenic molecule that can potentiate endogenous VEGF. We showed that PR1P bound VEGF directly and enhanced VEGF binding to endothelial cells and to VEGF receptors VEGFR2 and neuropilin-1. PR1P increased angiogenesis in the murine corneal micropocket assay when combined with VEGF, but had no activity without added VEGF. In addition, PR1P also enhanced angiogenesis in murine choroidal neovascularization and wound-healing models and augmented reperfusion in a murine hind-limb ischemia model. Together our data suggest that PR1P enhanced angiogenesis by potentiating the activity of endogenous VEGF. In so doing, this novel therapy takes advantage of endogenous VEGF gradients generated in injured tissues and may improve the efficacy of and avoid systemic toxicity seen with previous VEGF therapies.

Keywords

VEGF prominin-1 Angiogenesis Pro-angiogenesis therapy Peptide PR1P 

Copyright information

© Springer Science+Business Media Dordrecht 2017

Authors and Affiliations

  • Avner Adini
    • 1
    • 3
  • Irit Adini
    • 1
  • Zai-long Chi
    • 1
  • Ratmir Derda
    • 2
  • Amy E. Birsner
    • 1
  • Benjamin D. Matthews
    • 1
    • 3
  • Robert J. D’Amato
    • 1
    • 4
  1. 1.Vascular Biology Program, Department of Surgery, Boston Children’s HospitalHarvard Medical SchoolBostonUSA
  2. 2.Department of ChemistryUniversity of AlbertaEdmontonCanada
  3. 3.Department of Medicine, Boston Children’s HospitalHarvard Medical SchoolBostonUSA
  4. 4.Department of OphthalmologyHarvard Medical SchoolBostonUSA

Personalised recommendations